

# **Certificate of Analysis**

Print Date: Feb 26th 2020

www.tocris.com

Product Name: TCN 201 Catalog No.: 4154 Batch No.: 2

CAS Number: 852918-02-6

IUPAC Name: 3-Chloro-4-fluoro-*N*-[4-[[2-(phenylcarbonyl)hydrazino]carbonyl]benzyl]benzenesulfonamide

# 1. PHYSICAL AND CHEMICAL PROPERTIES

**Batch Molecular Formula:** C<sub>21</sub>H<sub>17</sub>CIFN<sub>3</sub>O<sub>4</sub>S

**Batch Molecular Weight:** 461.89 **Physical Appearance:** White solid

Solubility: DMSO to 100 mM Storage: Store at +4°C

**Batch Molecular Structure:** 

## 2. ANALYTICAL DATA

**HPLC:** Shows 99.2% purity

<sup>1</sup>H NMR: Consistent with structure

Mass Spectrum: Consistent with structure

Microanalysis: Carbon Hydrogen Nitrogen

Theoretical 54.61 3.71 9.1 Found 54.71 3.68 9.14

Caution - Not Fully Tested • Research Use Only • Not For Human or Veterinary Use



# **Product Information**

Print Date: Feb 26th 2020

www.tocris.com

Product Name: TCN 201 Catalog No.: 4154 Batch No.: 2

CAS Number: 852918-02-6

IUPAC Name: 3-Chloro-4-fluoro-*N*-[4-[[2-(phenylcarbonyl)hydrazino]carbonyl]benzyl]benzenesulfonamide

### **Description:**

NMDA receptor antagonist selective for GluN1/GluN2A (formally NR1/NR2A) over GluN1/GluN2B (formally NR1/NR2B) containing receptors (pIC $_{50}$  values are 6.8 and <4.3, respectively, in human recombinant GluN1/GluN2A (formally NR1/NR2A) and GluN1/GluN2B (formally NR1/NR2B) FLIPR/Ca $^{2+}$  assays). Please refer to IUPHAR Guide to Pharmacology for the most recent naming conventions.

#### **Physical and Chemical Properties:**

Batch Molecular Formula: C<sub>21</sub>H<sub>17</sub>CIFN<sub>3</sub>O<sub>4</sub>S

Batch Molecular Weight: 461.89 Physical Appearance: White solid

Minimum Purity: ≥99%

#### **Batch Molecular Structure:**

Storage: Store at +4°C

# Solubility & Usage Info:

DMSO to 100 mM

### Stability and Solubility Advice:

Some solutions can be difficult to obtain and can be encouraged by rapid stirring, sonication or gentle warming (in a 45-60°C water bath).

Information concerning product stability, particularly in solution, has rarely been reported and in most cases we can only offer a general guide. Our standard recommendations are:

SOLIDS: Provided storage is as stated on the product label and the vial is kept tightly sealed, the product can be stored for up to 6 months from date of receipt.

SOLUTIONS: We recommend that stock solutions, once prepared, are stored aliquoted in tightly sealed vials at -20°C or below and used within 1 month. Wherever possible solutions should be made up and used on the same day.

#### References:

**Gipson** *et al* (2013) Reinstatement of nicotine seeking is mediated by glutamatergic plasticity. Proc.Natl.Acad.Sci.U S A [Epub ahead of print]. PMID: 23671067.

**Edman** et al (2012) TCN 201 selectively blocks GluN2A-containing NMDARs in a GluN1 co-agonist dependent but non-competitive manner. Neuropharmacology 63 441. PMID: 22579927.

**Hansen** *et al* (2012) Subunit-selective allosteric inhibition of glycine binding to NMDA receptors. J.Neurosci. **32** 6197. PMID: 22553026. **Shin** *et al* (2011) Subtype selective NMDA receptor antagonists induce recovery of synapses lost following exposure to HIV-1 Tat. Br.J.Pharmacol. **166** 1002. PMID: 22142193.

**Bettini** et al (2010) Identification and characterization of novel NMDA receptor antagonists selective for NR2A- over NR2B-containing receptors. J.Pharm.Exp.Ther. **335** 644. PMID: 20810618.

Caution - Not Fully Tested • Research Use Only • Not For Human or Veterinary Use